JAHA:血清生长分化因子15水平与缺血性卒中后抑郁相关

2022-01-03 MedSci原创 MedSci原创

缺血性卒中急性期血清GDF-15水平升高与PSD独立相关,表明GDF-15水平可能是PSD有价值的预后生物标志物。

卒中是导致死亡和长期残疾的主要原因,已成为全球重要的公共卫生问题。在卒中幸存者的所有并发症中,卒中后抑郁症(PSD)是最常见的精神问题。2005年,Hackett等人进行的一项系统评价估计了PSD的发生率高达33%(95%CI为29%-36%)。PSD引起的后果不仅限于心理健康;它还会对康复和生活质量产生不利影响,并增加患者卒中后死亡的风险。

但是血清生长分化因子15(GDF-15)对PSD的影响仍然未知。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,该研究的目的是探讨缺血性卒中患者血清GDF-15水平与PSD之间的相关性。

该研究基于来自CATIS(中国急性缺血性卒中抗高血压试验)的随机样本,分析了来自7家参与医院的572名患者的GDF-15水平。研究结果是缺血性卒中后3个月出现的抑郁症状(汉密尔顿抑郁量表评分≥8)。

该研究共有231名(40.4%)卒中患者在3个月内经历了PSD。与最低三分位数相比,与血清GDF-15水平最高三分位数相关的PSD的多变量调整比值比为2.92(95%CI为1.36-6.27)。GDF-15水平对数转换后每增加1个SD与PSD风险增加42%(95%CI为2%-97%)相关,并且观察到血清GDF-15水平与PSD风险之间存在线性关联(线性P=0.006)。

由此可见,缺血性卒中急性期血清GDF-15水平升高与PSD独立相关,表明GDF-15水平可能是PSD有价值的预后生物标志物。

原始出处:

Yuhan Zang,et al.Serum Growth Differentiation Factor 15 Levels Are Associated With Depression After Ischemic Stroke.JAHA.2022.https://www.ahajournals.org/doi/full/10.1161/JAHA.121.022607

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655015, encodeId=7c3216550150f, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Fri Apr 29 08:00:32 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671455, encodeId=6cac16e14558a, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Feb 23 18:00:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806488, encodeId=4a261806488dd, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 16 11:00:32 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893462, encodeId=a13c1893462cc, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Mar 31 09:00:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268721, encodeId=3f551268e21a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jan 05 02:00:32 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180323, encodeId=4e0211803238b, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Oiaecicujl2wfpBkKyhZ6gwISPy9rBt6nOxLXG0QhflNATVnicPmib6zX885nmcdZh0mEqTbaSWeftY7CcwDnSvduw/132, createdBy=bca42490282, createdName=米师, createdTime=Tue Jan 04 10:09:15 CST 2022, time=2022-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655015, encodeId=7c3216550150f, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Fri Apr 29 08:00:32 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671455, encodeId=6cac16e14558a, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Feb 23 18:00:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806488, encodeId=4a261806488dd, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 16 11:00:32 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893462, encodeId=a13c1893462cc, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Mar 31 09:00:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268721, encodeId=3f551268e21a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jan 05 02:00:32 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180323, encodeId=4e0211803238b, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Oiaecicujl2wfpBkKyhZ6gwISPy9rBt6nOxLXG0QhflNATVnicPmib6zX885nmcdZh0mEqTbaSWeftY7CcwDnSvduw/132, createdBy=bca42490282, createdName=米师, createdTime=Tue Jan 04 10:09:15 CST 2022, time=2022-01-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655015, encodeId=7c3216550150f, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Fri Apr 29 08:00:32 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671455, encodeId=6cac16e14558a, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Feb 23 18:00:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806488, encodeId=4a261806488dd, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 16 11:00:32 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893462, encodeId=a13c1893462cc, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Mar 31 09:00:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268721, encodeId=3f551268e21a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jan 05 02:00:32 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180323, encodeId=4e0211803238b, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Oiaecicujl2wfpBkKyhZ6gwISPy9rBt6nOxLXG0QhflNATVnicPmib6zX885nmcdZh0mEqTbaSWeftY7CcwDnSvduw/132, createdBy=bca42490282, createdName=米师, createdTime=Tue Jan 04 10:09:15 CST 2022, time=2022-01-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655015, encodeId=7c3216550150f, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Fri Apr 29 08:00:32 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671455, encodeId=6cac16e14558a, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Feb 23 18:00:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806488, encodeId=4a261806488dd, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 16 11:00:32 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893462, encodeId=a13c1893462cc, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Mar 31 09:00:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268721, encodeId=3f551268e21a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jan 05 02:00:32 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180323, encodeId=4e0211803238b, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Oiaecicujl2wfpBkKyhZ6gwISPy9rBt6nOxLXG0QhflNATVnicPmib6zX885nmcdZh0mEqTbaSWeftY7CcwDnSvduw/132, createdBy=bca42490282, createdName=米师, createdTime=Tue Jan 04 10:09:15 CST 2022, time=2022-01-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655015, encodeId=7c3216550150f, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Fri Apr 29 08:00:32 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671455, encodeId=6cac16e14558a, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Feb 23 18:00:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806488, encodeId=4a261806488dd, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 16 11:00:32 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893462, encodeId=a13c1893462cc, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Mar 31 09:00:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268721, encodeId=3f551268e21a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jan 05 02:00:32 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180323, encodeId=4e0211803238b, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Oiaecicujl2wfpBkKyhZ6gwISPy9rBt6nOxLXG0QhflNATVnicPmib6zX885nmcdZh0mEqTbaSWeftY7CcwDnSvduw/132, createdBy=bca42490282, createdName=米师, createdTime=Tue Jan 04 10:09:15 CST 2022, time=2022-01-04, status=1, ipAttribution=)]
    2022-01-05 zhaohui6731
  6. [GetPortalCommentsPageByObjectIdResponse(id=1655015, encodeId=7c3216550150f, content=<a href='/topic/show?id=c8bf6960920' target=_blank style='color:#2F92EE;'>#生长分化因子15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69609, encryptionId=c8bf6960920, topicName=生长分化因子15)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c724602049, createdName=qingrejiedu, createdTime=Fri Apr 29 08:00:32 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671455, encodeId=6cac16e14558a, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Wed Feb 23 18:00:32 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806488, encodeId=4a261806488dd, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Aug 16 11:00:32 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893462, encodeId=a13c1893462cc, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Mar 31 09:00:32 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268721, encodeId=3f551268e21a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Wed Jan 05 02:00:32 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180323, encodeId=4e0211803238b, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Oiaecicujl2wfpBkKyhZ6gwISPy9rBt6nOxLXG0QhflNATVnicPmib6zX885nmcdZh0mEqTbaSWeftY7CcwDnSvduw/132, createdBy=bca42490282, createdName=米师, createdTime=Tue Jan 04 10:09:15 CST 2022, time=2022-01-04, status=1, ipAttribution=)]
    2022-01-04 米师

    感谢分享

    0

相关资讯

Liver Int:生长分化因子15能够预测肝组织穿刺证实的非酒精性脂肪肝患者的晚期纤维化分期

研究结果表明,GDF15可作为诊断NAFLD晚期纤维化的一种新的生物标志物。

盘点:生长分化因子15近期重要研究一览

 生长分化因子15 (GDF-15)是一种factor-β超家族的抗炎细胞因子。GDF-15的循环水平与肥胖或糖尿病患者的高血糖有关以及多种疾病相关。那么近期有关生长分化因子15的研究有哪些呢?请随梅斯小编一起来回顾一下

Heart:生长分化因子15作为肺动脉高压患者死亡率的候选预测指标

由此可见,PH成人较高的GDF-15与死亡或移植风险增加有关,不论年龄和NT-proBNP水平。作为非特异性生物标志物,GDF-15对于检测低危患者尤其有用。

JAHA:先兆子痫诊断前循环中生长分化因子15水平升高

循环中GDF-15在更可能发生先兆子痫或被诊断出先兆子痫的女性中升高。它可能具有作为临床生物标志物的价值,包括改善sFlt-1/PlGF比值敏感性的潜力。

JAHA:生长分化因子15和NT-proBNP作为血管性脑损伤和痴呆症的生物标记

血浆GDF15和NT-proBNP升高与60岁以上参与者磁共振成像血管性脑损伤、较差的神经认知功能以及发生痴呆的风险增加有关。